TY - JOUR
T1 - Neural indices of emotional reactivity and regulation predict course of PTSD symptoms in combat-exposed veterans
AU - Fitzgerald, Jacklynn M.
AU - Gorka, Stephanie M.
AU - Kujawa, Autumn
AU - DiGangi, Julia A.
AU - Proescher, Eric
AU - Greenstein, Justin E.
AU - Aase, Darrin M.
AU - Schroth, Christopher
AU - Afshar, Kaveh
AU - Kennedy, Amy E.
AU - Hajcak, Greg
AU - Phan, K. Luan
N1 - Funding Information:
This research was supported by Award Number I01CX000913 from the Clinical Science Research & Development Service of the VA Office of Research and Development (KLP). JMF, SMG, AK, JAD, EP, JEG, DMA, CS, KA, AEK, and GH have no disclosures to report.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/3/2
Y1 - 2018/3/2
N2 - After diagnosis, veterans with posttraumatic stress disorder (PTSD) display significant variability in the natural course of illness (Bonanno et al., 2012)). Cross-sectional work reveals that abnormal neural response during emotion reactivity—measured using the late positive potential (LPP)—correlates with PTSD symptom severity; however, whether the LPP during emotional reactivity and regulation predicts symptoms over time is unknown. The current study examined the LPP during emotion reactivity and regulation as predictors of PTSD symptoms over one year in OEF/OIF/OND combat-exposed veterans. At baseline, participants completed an Emotion Regulation Task (ERT) during electroencephalogram recording. The Clinician Administered PTSD Scale (CAPS) was completed at baseline (N = 86), 6-months (N = 54) and 1-year (N = 49) later. During ERT, participants viewed negative pictures; partway through they were instructed to “reappraise” (i.e., reduce negative affect/regulate) or “look” (i.e., passively react). Change in LPP during emotional reactivity (ΔLPP-E) and reappraisal (ΔLPP-R) were calculated and used in multilevel mixed modeling to predict CAPS over time. Findings demonstrated that deficiency in reappraisal (ΔLPP-R) predicted more overall symptoms over time, while greater neural responses to emotion (ΔLPP-E) and greater change in neural response as a function of reappraisal (ΔLPP-R) predicted a decline in avoidance symptoms over time. Together, results support the utility of neural markers of emotional reactivity and regulation as predictors of PTSD symptoms—and change in symptoms—across one year.
AB - After diagnosis, veterans with posttraumatic stress disorder (PTSD) display significant variability in the natural course of illness (Bonanno et al., 2012)). Cross-sectional work reveals that abnormal neural response during emotion reactivity—measured using the late positive potential (LPP)—correlates with PTSD symptom severity; however, whether the LPP during emotional reactivity and regulation predicts symptoms over time is unknown. The current study examined the LPP during emotion reactivity and regulation as predictors of PTSD symptoms over one year in OEF/OIF/OND combat-exposed veterans. At baseline, participants completed an Emotion Regulation Task (ERT) during electroencephalogram recording. The Clinician Administered PTSD Scale (CAPS) was completed at baseline (N = 86), 6-months (N = 54) and 1-year (N = 49) later. During ERT, participants viewed negative pictures; partway through they were instructed to “reappraise” (i.e., reduce negative affect/regulate) or “look” (i.e., passively react). Change in LPP during emotional reactivity (ΔLPP-E) and reappraisal (ΔLPP-R) were calculated and used in multilevel mixed modeling to predict CAPS over time. Findings demonstrated that deficiency in reappraisal (ΔLPP-R) predicted more overall symptoms over time, while greater neural responses to emotion (ΔLPP-E) and greater change in neural response as a function of reappraisal (ΔLPP-R) predicted a decline in avoidance symptoms over time. Together, results support the utility of neural markers of emotional reactivity and regulation as predictors of PTSD symptoms—and change in symptoms—across one year.
UR - http://www.scopus.com/inward/record.url?scp=85034860830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034860830&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2017.11.005
DO - 10.1016/j.pnpbp.2017.11.005
M3 - Article
C2 - 29122638
AN - SCOPUS:85034860830
SN - 0278-5846
VL - 82
SP - 255
EP - 262
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
ER -